NasdaqCM - Nasdaq Real Time Price USD

iSpecimen Inc. (ISPC)

Compare
2.5507
-0.1293
(-4.81%)
As of 11:50:12 AM EST. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
10,390.7020
9,928.1840
10,402.3030
11,135.3030
8,184.1060
Cost of Revenue
5,405.7460
4,820.2680
4,756.9650
5,249.0130
3,585.4770
Gross Profit
4,984.9560
5,107.9160
5,645.3380
5,886.2900
4,598.6290
Operating Expense
14,743.5690
16,277.2650
15,831.4200
11,811.5360
7,005.0090
Operating Income
-9,758.6130
-11,169.3490
-10,186.0820
-5,925.2460
-2,406.3800
Net Non Operating Interest Income Expense
-147.4130
108.9650
-69.6180
-2,091.2840
-2,096.3580
Other Income Expense
382.0710
-39.1040
9.7780
-945.2850
-149.3460
Pretax Income
-9,523.9550
-11,099.4880
-10,245.9220
-8,961.8150
-4,652.0840
Net Income Common Stockholders
-9,523.9550
-11,099.4880
-10,245.9220
-8,961.8150
-4,652.0840
Diluted NI Available to Com Stockholders
-9,523.9550
-11,099.4880
-10,245.9220
-8,961.8150
-4,652.0840
Basic EPS
-18.12
-24.60
-23.20
-41.80
-21.93
Diluted EPS
-18.12
-24.60
-23.20
-41.80
-21.93
Basic Average Shares
541.4720
452.0670
442.2150
214.3710
212.1260
Diluted Average Shares
541.4720
452.0670
442.2150
214.3710
212.1260
Total Operating Income as Reported
-9,758.6130
-11,169.3490
-10,186.0820
-5,925.2460
-2,406.3800
Total Expenses
20,149.3150
21,097.5330
20,588.3850
17,060.5490
10,590.4860
Net Income from Continuing & Discontinued Operation
-9,523.9550
-11,099.4880
-10,245.9220
-8,961.8150
-4,652.0840
Normalized Income
-9,523.9550
-11,099.4880
-10,245.9220
-8,061.0610
-4,493.0840
Interest Income
88.1400
339.7500
169.3450
11.3970
0.4370
Interest Expense
235.5530
230.7850
238.9630
2,102.6810
2,096.7950
Net Interest Income
-147.4130
108.9650
-69.6180
-2,091.2840
-2,096.3580
EBIT
-9,288.4020
-10,868.7030
-10,006.9590
-6,859.1340
-2,555.2890
EBITDA
-6,961.7320
-8,753.5550
-8,801.7600
-5,855.1370
-1,735.6020
Reconciled Cost of Revenue
5,405.7460
4,820.2680
4,756.9650
5,249.0130
3,585.4770
Reconciled Depreciation
2,326.6700
2,115.1480
1,205.1990
1,003.9970
819.6870
Net Income from Continuing Operation Net Minority Interest
-9,523.9550
-11,099.4880
-10,245.9220
-8,961.8150
-4,652.0840
Total Unusual Items Excluding Goodwill
--
--
--
-900.7540
-159.0000
Total Unusual Items
--
--
--
-900.7540
-159.0000
Normalized EBITDA
-6,961.7320
-8,753.5550
-8,801.7600
-4,954.3830
-1,576.6020
12/31/2020 - 6/17/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

APDN Applied DNA Sciences, Inc.
0.1910
-3.39%
 
NDRA ENDRA Life Sciences Inc.
5.62
-4.54%
 
ACRS Aclaris Therapeutics, Inc.
2.4000
-2.83%
 
SHC Sotera Health Company
12.81
-2.27%
 
OCX OncoCyte Corporation
2.1100
-4.52%
 
MYNZ Mainz Biomed N.V.
4.2900
+0.23%
 
TTOO T2 Biosystems, Inc.
0.3230
+0.94%
 
GTG.AX Genetic Technologies Limited
0.0390
0.00%
 
GNTLF Genetic Technologies Limited
1.0000
0.00%
 
BIAF bioAffinity Technologies, Inc.
0.7326
-9.56%